Get the Stockscreener App
0.4959
5.47%
-0.0287
After Hours:
.52
0.0241
+4.86%
Longeveron Inc stock is traded at $0.4959, with a volume of 510.19K.
It is down -5.47% in the last 24 hours and down -2.95% over the past month.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.
See More
Previous Close:
$0.5246
Open:
$0.525
24h Volume:
510.19K
Relative Volume:
1.42
Market Cap:
$10.58M
Revenue:
$1.44M
Net Income/Loss:
$-21.34M
P/E Ratio:
-0.3709
EPS:
-1.3371
Net Cash Flow:
$-17.38M
1W Performance:
-14.50%
1M Performance:
-2.95%
6M Performance:
-37.37%
1Y Performance:
-64.58%
1-Day Range:
$0.491
$0.5348
1-Week Range:
$0.491
$0.5912
52-Week Range:
$0.491
$1.9198
Longeveron Inc Stock (LGVN) Company Profile
Name
Longeveron Inc
Sector
Industry
Phone
305-302-7158
Address
1951 NW 7TH AVENUE, MIAMI
Compare LGVN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LGVN
Longeveron Inc
|
0.4959 | 11.19M | 1.44M | -21.34M | -17.38M | -1.3371 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Longeveron Inc Stock (LGVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-24 | Initiated | ROTH MKM | Buy |
Longeveron Inc Stock (LGVN) Latest News
Aug Sentiment: Is Longeveron Inc exposed to currency risks2025 Market Outlook & Weekly Breakout Watchlists - baoquankhu1.vn
Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them - Cantech Letter
Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them - Benzinga
Longeveron Inc. (LGVN) asks shareholders to OK 1:5–1:20 reverse split to meet Nasdaq - Stock Titan
LGVN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
LGVN: Trial Results Encouraging - Research Tree
LGVN Should I Buy - Intellectia AI
Longeveron Reports Positive Phase 2b Clinical Trial Results - Intellectia AI
Longeveron Inc. Reports Positive Trial Results for Age-Related Therapy - Intellectia AI
Longeveron Shares Fall After Releasing Phase 2b Data From Age-Related Frailty Study - marketscreener.com
Longeveron publishes phase 2b stem cell trial results in journal - Investing.com
LGVN Shares Rise After Investigational Therapy Shows Improvement In Age-Related Frailty In Study - Stocktwits
LGVN Shares Rise After Investigational Therapy Shows Improvement In Age-Related Frailty Study - Stocktwits
Longeveron publishes phase 2b stem cell trial results in journal By Investing.com - Investing.com South Africa
Longeveron Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell - Bitget
Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell - The Manila Times
Stem cell therapy helps frailty patients walk farther in Longeveron trial - Stock Titan
Longeveron launches offering of up to 11.8M shares via warrants and stock units - MSN
Aug Movers: Can Longeveron Inc outperform in the next rallyEarnings Summary Report & Safe Entry Momentum Stock Tips - baoquankhu1.vn
Q1 Earnings Forecast for Longeveron Issued By Zacks Research - Defense World
Will Longeveron Inc. stock hit new highs in YEARMarket Performance Recap & Intraday High Probability Alerts - mfd.ru
Longeveron (LGVN) Projected to Post Quarterly Earnings on Friday - Defense World
Trade Recap: Does Longeveron Inc offer margin of safetyJuly 2025 Sentiment & Free High Return Stock Watch Alerts - baoquankhu1.vn
LGVN SEC FilingsLongeveron Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Is Longeveron Inc. a strong candidate for buy and holdQuarterly Risk Review & Consistent Profit Focused Trading Strategies - mfd.ru
LGVN: New CEO and Fresh Cost Reductions - Research Tree
Longeveron Appoints Stephen Willard as CEO - citybiz
Surprises Report: Is Longeveron Inc stock a value trapJuly 2025 Breakouts & Risk Managed Investment Strategies - baoquankhu1.vn
Longeveron Appoints New CEO to Lead Pivotal Clinical Trials - National Today
Longeveron Appoints New CEO Amid Cost-Cutting Initiatives - The Globe and Mail
Is Longeveron Inc. on track to beat earningsJuly 2025 Weekly Recap & Weekly Watchlist of Top Performers - mfd.ru
Longeveron appoints Stephen Willard as new CEO ahead of pivotal trial results - Investing.com Australia
Longeveron appoints Stephen Willard as new CEO ahead of pivotal trial results By Investing.com - Investing.com South Africa
Longeveron Appoints New CEO to Drive Growth - Intellectia AI
Longeveron Inc. Appoints Stephen H. Willard as New CEO, Succeeding Than Powell - Quiver Quantitative
Longeveron® Appoints Stephen H. Willard as Chief Executive Officer - The Manila Times
New Longeveron CEO steps in as pivotal stem cell trial nears - Stock Titan
Gains Recap: Is Longeveron Inc. stock supported by strong fundamentalsEarnings Overview Report & Long-Term Investment Growth Plans - mfd.ru
Is Longeveron Inc. exposed to currency risksQuarterly Market Review & High Accuracy Trade Alerts - mfd.ru
How cyclical is Longeveron Incs revenue streamEarnings Growth Summary & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Is Longeveron Inc. still a buy after recent gains2025 Earnings Surprises & Consistent Return Investment Signals - mfd.ru
Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program - The Manila Times
Congress renews voucher that may speed Longeveron heart therapy for babies - Stock Titan
Merger Talk: Is WABC part of any major indexVolume Spike & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Market Catalysts: Will Longeveron Inc benefit from rising consumer demand2025 Earnings Surprises & Weekly Top Gainers Trade List - baoquankhu1.vn
Longeveron receives Japanese patent for stem cell potency assay methods By Investing.com - Investing.com South Africa
Longeveron receives Japanese patent for stem cell potency assay methods - Investing.com
Longeveron® Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs) - The Manila Times
Longeveron prepares for pivotal HLHS therapy data with FDA meeting By Investing.com - Investing.com Nigeria
Gainers Report: Whats the outlook for CrowdStrike Holdings Incs sectorTake Profit & Growth Focused Stock Reports - baoquankhu1.vn
Published on: 2026-01-27 00:29:51 - baoquankhu1.vn
Longeveron Inc Stock (LGVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Longeveron Inc Stock (LGVN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Soffer Rock | Director |
May 29 '25 |
Sale |
1.30 |
10,000 |
13,000 |
220,034 |
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):